Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts

Cancer Immunology, Immunotherapy

Volumn 65, Issue 5, 2016, Pages 525-536

  Poh, Su Li ^a   Linn, Yeh Ching ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cytokine induced killer cells; Immune checkpoint inhibitors; Inhibitory receptor and ligand; Myeloid leukaemia

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; CD200 RECEPTOR; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; CD200R1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; HAVCR2 PROTEIN, HUMAN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; MYELOID LEUKEMIA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE DISEASE; CANCER STEM CELL; CYTOTOXICITY TEST; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; PROCEDURES; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; CTLA-4 ANTIGEN; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKEMIA, MYELOID; MEMBRANE PROTEINS; NEOPLASTIC STEM CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, CELL SURFACE; RECEPTORS, KIR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84960327660     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1815-8     Document Type: Article

References (48)

1. Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116(1):78–86
2. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92(9):3318–3327
3. Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD (2006) Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer 119(6):1377–1382
4. Thanendrarajan S, Kim Y, Schmidt-Wolf I (2012) New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 12(5):565–572
5. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Diego LG, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D (2012) Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12(6):673–684
6. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149
7. Linn YC (2013) Cytokine-induced killer cells for leukemia—from bench to bedside. Ann Hematol 92(suppl 1):S47
8. Jäkel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IGH (2014) Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014:897214
9. Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P (2012) The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14(1):91–103
10. Durrieu L, Gregoire-Gauthier J, Dieng MM, Fontaine F, le Deist F, Haddad E (2012) Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 14(10):1245–1257
11. Marin V, Pizzitola I, Agostoni V, Attianese GMPG, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E (2010) Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95(12):2144–2152
12. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IGH (2012) Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012:238924
13. Zou Y, Li F, Hou W, Sampath P, Zhang Y, Thorne SH (2014) Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells. Br J Cancer 110(8):1992–1999
14. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14(10):3044–3051
15. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D et al (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31(33):4199–4206
16. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319
17. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D (2012) A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120(22):4317–4323
18. Benson DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS (2012) A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22):4324–4333
19. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7(4):216–222
20. Linn YC, Lau SKJ, Liu BH, Ng LH, Yong HX, Hui KM (2009) Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 126(3):423–435
21. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M (2009) Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 37(5):616.e2–628.e2
22. Linn YC, Wang SM, Hui KM (2005) Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol 33(6):671–681
23. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B (1990) Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 76(12):2599–2605
24. Chan WC, Linn YC (2014) A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role. Cytotechnology. doi:10.1007/s10616-014-9825-x
25. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park JS, Kollia G, Taube JM, Anders R, Jure-Kunkel M, Novotny JJ, Taylor CR, Zhang X, Phillips T, Simmons P, Cogswell J (2013) Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31 (suppl; abstr 3016)
26. Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, Wang SD, Dong H, Chen L, Ogata K (2005) Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 11(16):5708–5717
27. + T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 39(9):2492–2501
28. Anderson AC (2014) Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2(5):393–398
29. Sierro S, Romero P, Speiser DE (2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15(1):91–101
30. Velders MP, ter Horst SA, Kast WM (2001) Prospect for immunotherapy of acute lymphoblastic leukemia. Leukemia 15(5):701–706
31. Baer MR, Stewart CC, Dodge RK, Leget G, Sulé N, Mrózek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97(11):3574–3580
32. van Bergen J, Koning F (2010) The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology 131(3):301–309
33. Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L, Olive D (2013) The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood 122(6):922–931
34. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72(4):887–896
35. del Rio ML, Jones ND, Buhler L, Norris P, Shintani Y, Ware CF, Rodriguez-Barbosa JI (2012) Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction. J Immunol 188(10):4885–4896
36. Rijkers ESK, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L (2008) The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 45(4):1126–1135
37. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194–4197
38. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, Darley RL (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3):566–568
39. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33(3):344–352
40. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917–927
41. Sanborn RE, Sharfman WH, Segal NH, Hodi FS, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Covello K, McDonald D, Kim SY, Gupta A, Wigginton JM, Gajewski TF (2014) A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol 32 (suppl; abstr TPS3115)
42. Rizvi NA, Infante JR, Gibney GT, Bertino EM, Cooley S, Lekatis K, Wigginton JM, Gutierrez AA, Gupta AK, Kim SY, Hodi FS (2013) A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors. J Clin Oncol 31 (suppl; abstr 3106)
43. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112(6):2563–2574
44. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D’Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A (2007) Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92(7):952–959
45. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS (2011) Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(11):1679–1687
46. Zhong RK, Loken M, Lane TA, Ball ED (2006) CTLA-4 blockade by a human mAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy 8(1):3–12
47. Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, Chuah C, Goh YT, Hwang W, Loh Y, Ng HJ, Suck G, Chan M, Koh M (2012) A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy 14(7):851–859
48. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, Hwang W, Loh Y, Goh YT, Suck G, Chan M, Koh M (2012) The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 47(7):957–966